An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of Locteron (Poly Active - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C.
Phase of Trial: Phase I/II
Latest Information Update: 23 Mar 2013
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms PLUS
- Sponsors Biolex
- 24 Apr 2009 Tolerability results presented at EASL 2009.
- 24 Apr 2009 Results were presented in a Biolex media release, and at the 44th Annual Meeting of the European Association for the Study of the Liver.
- 09 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.